The loss of productivity due to flu is staggering. Costs range as much as $20 billio a year. High mutation rates of the flu virus have hindered development of new drugs or vaccines. The secret lies in a small molecule which is attached to the host cell's surface. Each flu virus, no matter what strain, must remove this small molecule to escape the host cell to spread infection. Using data from space and earth grown crystals, researchers from the Center of Macromolecular Crystallography (CMC) are desining drugs to bind with this protein's active site. This lock and key fit reduces the spread of flu in the body by blocking its escape route. In collaboration with its corporate partner, the CMC has refined drug structure in preparation for clinical trials. Tested and approved relief is expected to reach drugstores by year 2004.

Ribbons is a program developed at UAB used worldwide to graphically depict complicated protein structures in a simplified format. The program uses sophisticated computer systems to understand the implications of protein structures. The Influenza virus remains a major causative agent for a large number of deaths among the elderly and young children and huge economic losses due to illness. Finding a cure will have a general impact both on the basic research of viral pathologists of fast evolving infectious agents and clinical treatment of influenza virus infection. The reproduction process of all strains of influenza are dependent on the same enzyme neuraminidase. Shown here is a segmented representation of the neuraminidase inhibitor compound sitting inside a cave-like contour of the neuraminidase enzyme surface. This cave-like formation present in every neuraminidase enzyme is the active site crucial to the flu's ability to infect. The space-grown crystals of neuraminidase have provided significant new details about the three-dimensional characteristics of this active site thus allowing researchers to design drugs that fit tighter into the site. Principal Investigator: Dr. Larry DeLucas